Endpoints News 生物医药· Kyle LaHucik·· 2026-10-05AI 评分39
CSL 支付 3.55 亿美元首付款共同开发 Alentis 的抗纤维化肾病与肝病药物
CSL to pay $355M upfront to co-develop Alentis’ kidney and liver drug
AI 导读
CSL 将支付 3.55 亿美元首付款,共同开发 Alentis Therapeutics 的抗纤维化药物。该协议涵盖肾病和肝病适应症,未来支付总额最高可达 12 亿美元。
正文
The Australian drugmaker CSL will pay $355 million for Alentis Therapeutics’ anti-fibrosis drug, plus as much as $1.2 billion in future payments.
Under the
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news